{
    "nctId": "NCT01942629",
    "briefTitle": "Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas",
    "officialTitle": "Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas",
    "overallStatus": "UNKNOWN",
    "conditions": "Lung Adenocarcinoma, Breast Adenocarcinoma, Pancreatic Ductal Adenocarcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "5 year overall survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who were treated at our institution for lung adenocarcinoma, breast adenocarcinoma, or pancreatic ductal adenocarcinoma.\n* Available histopathological diagnosis of the malignancy.\n\nExclusion Criteria:\n\n* Patients with inoperable tumors.\n* Patients with second primary tumor.\n* Patients with pathological blocks not enough for future slicing.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}